Macrogenics

MacroGenics presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo) for mCRPC at ESMO, showing encouraging antitumor activity with 6-month landmark rPFS rates of 69% and 70% in the 2.0 mg/kg and 2.7 mg/kg arms, respectively. Patients remained on vobra duo through a median of 6 doses, and the company expects mature median rPFS data no later than early 2025.

MacroGenics to present Phase 2 data of vobramitamab duocarmazine in mCRPC at ESMO Congress on Sept 15, 2024, followed by an investor call on Sept 16, 2024.

MSD and Daiichi Sankyo presented interim results from the Ideate-Lung01 trial at WCLC, showing the 12 mg/kg dose of ifinatamab deruxtecan (I-DXd) had a 54.8% overall response rate (ORR) in extensive-stage small cell lung cancer (SCLC) patients, with a disease control rate (DCR) of 90.5%. The higher dose also showed improved progression-free and overall survival. Safety concerns included interstitial lung disease and gastrointestinal toxicities, but no 'great surprises'. The companies have started phase 3 Ideate-Lung02 study.

The global Type 1 Diabetes (T1D) market is projected to grow at a CAGR of 17.2%, reaching US$ 38.63 Bn by 2029. Driven by increased awareness, technological advancements in insulin delivery, and government initiatives, the market faces challenges like high costs and biosimilars. North America leads, with APAC expected to grow significantly.

The FDA approved Johnson & Johnson's Rybrevant, a bispecific antibody for treating a specific mutation in non-small cell lung cancer. Bispecific antibodies, targeting two proteins simultaneously, are emerging as a promising treatment for various cancers, including lymphoma, leukemia, and multiple myeloma, with several drugs in advanced clinical trials.